Related Experiment Video
Updated: May 3, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors
Mark E McDonnell1, Haiyan Bian1, Jay Wrobel1
1Fox Chase Chemical Diversity Center, Inc., 3805 Old Easton Road, Doylestown, PA 18902, United States.
Abstract:
We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition.
Related Concept Videos
The JAK-STAT Signaling Pathway
Dipeptidyl Peptidase 4 Inhibitors
PI3K/mTOR/AKT Signaling Pathway
Inhibition of CDK Activity
Inhibitors of Viral Protein Synthesis
cAMP-dependent Protein Kinase Pathways

